BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Leukemia AND NF2, ACN, 4771, ENSG00000186575, P35240, SCH, Merlin, BANF AND Treatment
18 results:

  • 1. mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes nf2-deficient meningioma cellular models to IGF1R inhibition.
    Beauchamp RL; Erdin S; Witt L; Jordan JT; Plotkin SR; Gusella JF; Ramesh V
    J Biol Chem; 2021; 296():100157. PubMed ID: 33273014
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Cancer genomics of lung cancer including malignant mesothelioma: A brief overview of current status and future prospects.
    Jhanwar SC; Xu XL; Elahi AH; Abramson DH
    Adv Biol Regul; 2020 Dec; 78():100723. PubMed ID: 32992231
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Role and mechanism of autophagy-regulating factors in tumorigenesis and drug resistance.
    Usman RM; Razzaq F; Akbar A; Farooqui AA; Iftikhar A; Latif A; Hassan H; Zhao J; Carew JS; Nawrocki ST; Anwer F
    Asia Pac J Clin Oncol; 2021 Jun; 17(3):193-208. PubMed ID: 32970929
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Degradation of
    Wu TC; Hong YH; Tsai YH; Hsieh SL; Huang RH; Kuo CH; Huang CY
    Mar Drugs; 2020 Jun; 18(6):. PubMed ID: 32604764
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia.
    Robak P; Robak T
    Expert Opin Investig Drugs; 2017 Nov; 26(11):1249-1265. PubMed ID: 28942659
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Subclinical Hypothyroidism in Childhood Cancer Survivors.
    Lee HJ; Hahn SM; Jin SL; Shin YJ; Kim SH; Lee YS; Kim HS; Lyu CJ; Han JW
    Yonsei Med J; 2016 Jul; 57(4):915-22. PubMed ID: 27189285
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Collecting duct carcinoma of the kidney is associated with CDKN2A deletion and SLC family gene up-regulation.
    Wang J; Papanicolau-Sengos A; Chintala S; Wei L; Liu B; Hu Q; Miles KM; Conroy JM; Glenn ST; Costantini M; Magi-Galluzzi C; Signoretti S; Choueiri T; Gallucci M; Sentinelli S; Fazio VM; Poeta ML; Liu S; Morrison C; Pili R
    Oncotarget; 2016 May; 7(21):29901-15. PubMed ID: 27144525
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Uncommon histiocytic disorders: Rosai-Dorfman, juvenile xanthogranuloma, and Erdheim-Chester disease.
    Haroche J; Abla O
    Hematology Am Soc Hematol Educ Program; 2015; 2015():571-8. PubMed ID: 26637774
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation.
    van Besien K; Stock W; Rich E; Odenike O; Godley LA; O'Donnell PH; Kline J; Nguyen V; Del Cerro P; Larson RA; Artz AS
    Biol Blood Marrow Transplant; 2012 Jun; 18(6):913-21. PubMed ID: 22079470
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Molecular allelokaryotyping of relapsed pediatric acute lymphoblastic leukemia.
    Kawamata N; Ogawa S; Seeger K; Kirschner-Schwabe R; Huynh T; Chen J; Megrabian N; Harbott J; Zimmermann M; Henze G; Schrappe M; Bartram CR; Koeffler HP
    Int J Oncol; 2009 Jun; 34(6):1603-12. PubMed ID: 19424578
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine.
    Hewish M; Chau I; Cunningham D
    Recent Pat Anticancer Drug Discov; 2009 Jan; 4(1):54-72. PubMed ID: 19149688
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Phase II, randomized, multicenter, comparative study of peginterferon-alpha-2a (40 kD) (Pegasys) versus interferon alpha-2a (Roferon-A) in patients with treatment-naïve, chronic-phase chronic myelogenous leukemia.
    Lipton JH; Khoroshko N; Golenkov A; Abdulkadyrov K; Nair K; Raghunadharao D; Brummendorf T; Yoo K; Bergstrom B;
    Leuk Lymphoma; 2007 Mar; 48(3):497-505. PubMed ID: 17454589
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Establishment and characterization of a novel imatinib-sensitive chronic myeloid leukemia cell line MYL, and an imatinib-resistant subline MYL-R showing overexpression of Lyn.
    Ito T; Tanaka H; Kimura A
    Eur J Haematol; 2007 May; 78(5):417-31. PubMed ID: 17432977
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. [Neurofibromatosis: the most frequent hereditary tumor predisposition syndrome].
    Wimmer K
    Wien Med Wochenschr; 2005 Jun; 155(11-12):273-80. PubMed ID: 16035388
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. sch-66336 (sarasar) and other benzocycloheptapyridyl farnesyl protein transferase inhibitors: discovery, biology and clinical observations.
    Taveras AG; Kirschmeier P; Baum CM
    Curr Top Med Chem; 2003; 3(10):1103-14. PubMed ID: 12769711
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. [Von Recklinghausen's neurofibromatosis (neurofibromatosis type I)--a familial case report].
    Tasić S; Stojanović S; Poljacki M; Janjić Z; Jovanović-Privrodski J
    Med Pregl; 2000; 53(9-10):517-20. PubMed ID: 11320736
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. [The human genome--chromosome 22].
    Brdicka R
    Cas Lek Cesk; 1995 Nov; 134(22):727-30. PubMed ID: 8599811
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Effectiveness of an oral triazole for opportunistic mold infections in patients with cancer: experience with sch 39304.
    Anaissie EJ; Kontoyiannis DP; Vartivarian S; Kantarjian HM; O'Brien S; Giralt SA; Andersson BS; Karl C; Champlin RE; Bodey GP
    Clin Infect Dis; 1993 Dec; 17(6):1022-31. PubMed ID: 8110925
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.